In an elderly patient with bone pain, when should steroids be used, what dose and duration are recommended, and what monitoring and adjunctive measures are needed?

Steroid Use in Elderly Bone Pain

Steroids should be used in elderly patients with bone pain primarily for cancer-related bone metastases (dexamethasone 4-8 mg daily) or when initiating glucocorticoid therapy for other conditions, but the focus must shift immediately to preventing glucocorticoid-induced osteoporosis rather than treating existing bone pain with steroids. 1, 2, 3

When Steroids Are Indicated for Bone Pain

Cancer-Related Bone Pain

• Dexamethasone is the preferred corticosteroid for painful bone metastases, with 66% of palliative care providers prescribing it for the majority of patients with this condition 3
• Dosing: 8 mg daily divided twice daily is most common, though clinical trials comparing 4 mg versus 8 mg daily would be useful to establish optimal dosing 3
• Duration: Once started, steroids are typically continued indefinitely in palliative settings, though this should be balanced against side effects 3
• Steroids provide modest analgesic benefit when combined with opioids, NSAIDs, or acetaminophen for bone metastases 2, 4
• Steroids should NOT be used as primary therapy for bone pain—bisphosphonates (zoledronic acid) or denosumab are the bone-targeting agents of choice 1, 2

Spinal Cord Compression (Oncologic Emergency)

• Dexamethasone 16 mg/day is the standard dose when metastatic spinal cord compression is diagnosed 2
• Higher doses (36-96 mg/day) may be used, potentially preceded by 10-100 mg IV bolus 2
• Steroids should be given immediately upon clinical-radiological diagnosis 2
• Taper over 2 weeks following definitive treatment with radiotherapy or surgery 2

Critical Concern: Glucocorticoid-Induced Osteoporosis (GIOP)

When Elderly Patients Receive Steroids for Any Reason

The primary concern in elderly patients receiving steroids is preventing GIOP, not treating bone pain with steroids. 5, 6, 5, 6

Immediate Assessment Required (Within 6 Months)

• For all adults ≥40 years starting prednisone ≥2.5 mg/day for >3 months: 5, 6
  • Calculate FRAX score (fracture risk assessment tool) 5, 6
  • Obtain DEXA scan with vertebral fracture assessment (VFA) or spine x-rays 5, 6
  • Assess clinical fracture risk factors: prior fractures, fall history, weight loss, smoking, alcohol use 5, 6

Fracture Risk Stratification

Very High Risk (vertebral fracture risk increases 14-fold, hip fracture 3-fold): 5

• Prednisone ≥30 mg/day for ≥30 days OR cumulative dose ≥5 g/year
• Recent fracture (within 2 years) and/or vertebral fracture
• Age ≥70 years with recent hip/pelvis fracture

High Risk: 6

• FRAX 10-year major osteoporotic fracture risk ≥20% or hip fracture risk >3%
• Prednisone ≥7.5 mg/day for ≥6 months

Moderate Risk: 6

• FRAX 10-year major osteoporotic fracture risk <20%, hip >1% but <3%

Osteoporosis Prevention Protocol

Universal Measures (All Patients on Steroids ≥3 Months)

• Calcium: 1,000-1,200 mg elemental calcium daily (dietary plus supplementation) 6
• Vitamin D: Maintain serum 25(OH)D levels 30-50 ng/mL (typically requires 600-800 IU daily or more) 6
• Weight-bearing exercise, smoking cessation, limit alcohol to ≤2 servings/day 6

Pharmacologic Treatment Based on Risk

Very High Risk Patients: 5, 6, 5

• First choice: Anabolic agents (teriparatide/PTH) over bisphosphonates 5, 6, 5
• Alternative: Oral bisphosphonates strongly recommended over no treatment 5
• Conditional recommendations: IV bisphosphonates, denosumab, raloxifene, or romosozumab 5

High Risk Patients: 6

• Oral bisphosphonates strongly recommended as first-line 6
• Conditional recommendation: Denosumab or PTH/PTHrP over bisphosphonates 6

Moderate Risk Patients: 6

• Conditional recommendations: Oral or IV bisphosphonates, denosumab, or PTH/PTHrP 6

Low Risk Patients: 5

• Strongly recommend AGAINST osteoporosis therapy due to potential harms (osteonecrosis of jaw, atypical femur fractures, thromboembolic events) without clear benefit 5

Specific Dosing for Osteoporosis Prevention

• Bisphosphonates: 10 mg methylprednisolone or triamcinolone equivalent per facet joint; 40 mg per sacroiliac joint 7
• FRAX score calculation: Use glucocorticoid-adjusted FRAX if prednisone >7.5 mg/day 5, 6
• Consider starting bisphosphonates immediately in high-risk elderly patients (age ≥70) even before DEXA results if FRAX score indicates high risk 8

Monitoring Requirements

Bone Health Monitoring

• DEXA scans with VFA every 1-2 years while on glucocorticoids 6
• Reassess FRAX score at follow-up visits for patients ≥40 years 6
• Monitor for new fractures, fall risk, and vertebral compression fractures 5, 6

Steroid-Related Adverse Effects

• Monitor for: weight gain, hyperglycemia, hypertension, mood changes, infection risk, gastric ulceration 8
• Gastroprotection: Consider proton pump inhibitors, though practice varies 3
• Bone density changes demonstrable within days of starting corticosteroids 8

Critical Pitfalls to Avoid

• Do not use steroids as primary treatment for non-malignant bone pain in elderly patients—the risks of GIOP outweigh benefits 1
• Do not delay osteoporosis prevention in patients starting chronic steroids—fracture risk increases rapidly 8, 6
• Doses as low as 2.5 mg prednisone for >3 months impair bone integrity 9
• Increased fracture risk persists up to 1 year after stopping steroids 8
• Elderly patients (70-79 years) receive fewer fracture prevention prescriptions despite highest risk 10
• Sequential therapy is mandatory after discontinuing denosumab, romosozumab, or PTH/PTHrP to prevent rebound bone loss 5, 6